A Phase 2 interventional study of Pyrotinib in HER2-positive Breast Cancer, sponsored by The First Affiliated Hospital with Nanjing Medical University. Recruiting at 1 site in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-04-28.
Sponsored by The First Affiliated Hospital with Nanjing Medical University · Phase 2, Interventional, and Treatment
How we know · 5 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 101 studies testing pyrotinib in Breast Neoplasms — 49 open to participants now, 57 under way, 13 of them phase 3. pyrotinib · Breast Neoplasms.
Among the 101 studies testing pyrotinib in Breast Neoplasms, this one is the 38th largest by planned enrollment, is one of 8 that started in 2023, is one of 63 in phase 2, reaches primary completion later than 25 of the 56 other live ones, and was the 70th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →49 of the 101 studies testing pyrotinib in Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:
Peking University People's Hospital · Sites in China
Ages 18+
Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18–70 · Women only
Fudan University · Sites in China
Ages 18–75 · Women only
Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18–70 · Women only
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–75 · Women only
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years to 75 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
101 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 70 · Phase 3 19 · Phase 4 2
First in 2013; this study’s year is marked. 8 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 188 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 100 across the 101 interventional studies. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 101 have an industry lead sponsor. The 10 most frequent:
The First Affiliated Hospital with Nanjing Medical University is the lead sponsor of 569 studies on the registry; 317 are open to participants now.
57 studies in Breast Neoplasms by The First Affiliated Hospital with Nanjing Medical University: 39 open now, 40 under way, none of them phase 3. Of 9 finished, 0 (0%) have results posted.
Among the 57 studies in Breast Neoplasms by The First Affiliated Hospital with Nanjing Medical University, this one is the 9th largest by planned enrollment of the 44 interventional ones that give a count, is one of 9 that started in 2023, is one of 27 in phase 2, reaches primary completion later than 13 of the 39 other live ones, and was the 17th registered.
The First Affiliated Hospital with Nanjing Medical University’s Breast Neoplasms studies by the year they started, since 2016.
6 of the studies testing pyrotinib in Breast Neoplasms that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04290793Phase 3Hebei Medical University Fourth HospitalNeoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer | 2026-12-01 |
| NCT03980054Phase 3Jiangsu HengRui Medicine Co., Ltd.A Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer | 2027-06 |
| NCT04973319Phase 3Shengjing HospitalTrastuzumab Combined With Pertuzumab for Adjuvant Treatment of Breast Cancer After Neoadjuvant Therapy | 2027-08-01 |
| NCT06035679Youzhi ZhuPyrotinib Combined With Trastuzumab and Chemotherapy Neoadjuvant Therapy for HER2-positive Breast Cancer | 2026-11-30 |
| NCT07708194Tianjin Medical University Cancer Institute and HospitalEntinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure | 2027-02 |
Add all 6 to your calendar (.ics) → With an account.
Among the 101 studies testing pyrotinib in Breast Neoplasms, from their registry updates:
Among The First Affiliated Hospital with Nanjing Medical University’s 57 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
ExteNET study explored neratinib prolong anti-HER2 therapy after trastuzumab therapy found that it can improve disease-free survival in patients with lymph nodes positive; In addition, the subgroup of patients with residual tumors after neoadjuvant therapy was found to improve the survival. However, no conclusive conclusions were reached.
However, since the study was carried out early so only trastuzumab treatment was used, it is urgent to carry out research that is more in line with current clinical practice and bring more benefits to patients. To explore whether pyrotinib can further reduce the risk of recurrence from previously diagnosed HER2-positive breast cancer after treatment with trastuzumab and pertuzumab or T-DM1.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
pyrotinib 400mg orally daily for one year
Drug: Pyrotinib
Pyrotinib after anti-HER2 therapy(Trastuzumab combined with Pertuzumab or T-DM1)
Also known as: Pyrotinib maleate
Invasive Disease-free Survival (iDFS) at year 2
Invasive disease-free survival time is defined as the time from date of enrollment until the first disease recurrence or death from any cause.
Time frame: From enrollment until time of events up to 2 years
Disease-free Survival at year 2 (2y-DFS)
Disease-free survival time is defined as the time from date of enrollment until the first disease recurrence(including carcinoma in situ)or death from any cause.
Time frame: From enrollment until time of events up to 2 years
Overall Survival (OS)
Randomization to death from any cause
Time frame: Enrollment until death due to any cause, up to 10 years
Invasive Disease-free Survival (iDFS) at year 5
Invasive disease-free survival time is defined as the time from date of enrollment until the first disease recurrence or death from any cause.
Time frame: From enrollment until time of events up to 5 years
AEs and SAEs
Adverse events and Adverse events and serious adverse events according to CACTE 5.0
Time frame: From the first administration to one months after the last drug administration
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2023 (actual). Primary completion is estimated for Jun 2026, 37 months after the start.
Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's planned 37 months is below that.
Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pyrotinib
The First Affiliated Hospital with Nanjing Medical University →